27. The Committee decided that if no method of analysis acceptable to the Committee was recommended to monitor an MRL, the MRL should not be advanced beyond Step 7.
Triclabendazole
28. The MRLs for triclabendazole had been retained at Step 7 since the 8th Session as further data related to toxicity and total residues distribution and depletion had been likely to become available. No data had been submitted to JECFA but it was reported that new data were being developed by the manufacturer.
29. The Committee decided to advance the MRLs for muscle (cattle); liver and kidney (cattle); and muscle, liver and kidney (sheep) to Step 8 with the understanding that when new data became available they should be evaluated by JECFA. The MRL for fat (cattle, sheep) was retained at Step 7, as there was no recommended method of analysis.
Levamisole
30. The Committee decided to advance the MRL for liver (cattle, sheep, pigs) to Step 8 and to retain those for muscle, kidney, fat (cattle, sheep, pigs, poultry) and for liver (poultry) at Step 7 as these were not supported by methods of analysis.
Diminazene
31. The Committee decided to retain the MRLs for diminazene at Step 7 as they were not supported by methods of analysis. The Committee noted that a method of analysis was being developed by the manufacturer, and agreed that if the method was found satisfactory at its next session, the Committee would consider advancing the MRLs to Step 8.
